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Reprogramming of differentiated adult cells 
into  their  embryonic  state  was  demonstrated 
when oocytes implanted with nuclei of adult 
somatic cells gave rise to viable animals (Wilmut 
et al., 1997). However, the understanding of 
the molecular pathway of reprogramming had 
significantly progressed when specific transcrip-
tion factors, such as Oct4, Sox2, Klf4, and c-Myc, 
were shown to collectively induce reprogram-
ming of mouse fibroblasts into induced pluripo-
tent stem cells (iPSCs; Takahashi and Yamanaka, 
2006). Additional factors were reported to en-
hance reprogramming or to functionally substi-
tute some of the mentioned factors (Maherali 
and Hochedlinger, 2008).
The core embryonic stem cell (ESC) regula-
tory circuitry includes Oct4, Sox2, and Nanog, 
which regulate their own expression and the ex-
pression of other factors involved in self-renewal 
and  pluripotency  (Hochedlinger  et  al.,  2005). 
Although  genetic  experiments  established  that 
Oct4 and Sox2 are essential for pluripotency   
(Ivanova et al., 2006; Masui et al., 2007), the role 
of c-Myc and Klf4 in reprogramming is less clear.
Several reprogramming factors are known 
for their oncogenic activity, suggesting a tight 
link between stemness and cancer, and a possi-
ble involvement of reprogramming factors in 
the induction of cancer. Although c-Myc is a 
well known oncogene, Klf4 appears to posses 
both growth inhibitory and promoting capabil-
ities, depending on the cell type (Evans and Liu, 
2008). Oct4 can act as a dose-dependent onco-
genic fate determinant, and its ectopic expres-
sion promotes dysplasia in epithelial tissues 
(Gidekel et al., 2003; Hochedlinger et al., 2005). 
In addition, up-regulation of Oct4, Sox2, and 
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p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent 
state. As p53 is usually mutated in human tumors and many mutated forms of p53 gain 
novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell repro-
gramming. Our data indicate a novel gain of function (GOF) property for mut-p53, which 
markedly enhanced the efficiency of the reprogramming process compared with p53 defi-
ciency. Importantly, this novel activity of mut-p53 induced alterations in the characteristics 
of the reprogrammed cells. Although p53 knockout (KO) cells reprogrammed with only 
Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells express-
ing mutant p53 lost this capability and gave rise to malignant tumors. This novel GOF of 
mut-p53 is not attributed to its effect on proliferation, as both p53 KO and mut-p53 cells 
displayed similar proliferation rates. In addition, we demonstrate an oncogenic activity of 
Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors. 
Overall, our data show that reprogrammed cells with the capacity to differentiate into the 
three germ layers in vitro can form malignant tumors, suggesting that in genetically  
unstable cells, such as those in which p53 is mutated, reprogramming may result in the 
generation of cells with malignant tumor-forming potential.
© 2010 Sarig et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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differentiation (Matas et al., 2004; Shaulsky et al., 1991) and, 
thus, may promote the reverse process of dedifferentiation.
Our main goal was to study the role of mut-p53 in so-
matic cell reprogramming and to follow the in vivo fate of 
reprogrammed p53-deficient or mutated cells. To that end, 
we induced reprogramming of mouse embryonic fibroblasts 
(MEFs) that differ in their p53 status. WT, KD, KO, or mu-
tant (mut-p53) knockin MEFs were reprogrammed by Oct4, 
Sox2, and Klf4 (three factors) or by only Oct4 and Sox2 (two 
factors). As previously reported (Hanna et al., 2009; Hong et al., 
2009; Kawamura et al., 2009; Li et al., 2009; Marión et al., 
2009; Utikal et al., 2009), we observed that p53 KD en-
hances  the  process  of  reprogramming.  More  importantly, 
however, we found that reprogramming of p53 KO MEFs 
with three factors led to the development of cells with a po-
tential to form malignant tumors that occasionally displayed 
differentiated regions. In contrast, p53 KO cells reprogrammed 
with two factors maintained their pluripotent capacity also   
in vivo. Finally, mut-p53 exhibited a novel GOF activity by 
further enhancing reprogramming efficiency and reducing 
the differentiation capacity of MEFs reprogrammed by two 
factors in vivo. This novel GOF of mut-p53 is not attributed 
to its effect on proliferation rate, as both p53 KO and mut-p53 
cells displayed a similar proliferation pattern, but the latter were 
much more prone for reprogramming and were more tumori-
genic in vivo.
RESULTS
Enhanced reprogramming of MEFs expressing mut-p53 
compared with p53 KO MEFs using Oct4, Sox2, and Klf4
In agreement with previous studies (Zhao et al., 2008; Hanna 
et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li   
et al., 2009; Marión et al., 2009; Utikal et al., 2009), we found 
that p53 counteracts the reprogramming process. By knocking 
down endogenous WT p53 in MEFs (p53 KD), we observed 
an enhanced reprogramming efficiency. Characterization of 
p53 KD iPSC clones demonstrated their ability to differenti-
ate into typical cells of the three germ layers in vitro and in vivo, 
as evident by their ability to form teratomas and chimeric mice 
(Fig. S1). Thus, reprogramming of p53 KD cells resulted in the 
formation of bona fide iPSC.
Although p53 KD is quite efficient in MEFs, it does not 
completely eliminate p53 expression (Fig. S1 A and Fig. S2 B). 
Hence, we compared the effect of p53 KO to p53 KD on re-
programming efficiency. To this end, we infected control, 
p53 KD, and p53 KO MEFs with the three factors (Oct4, 
Sox2, and Klf4) together with GFP. Indeed, the fastest and 
highest  reprogramming  yield  was  achieved  with  p53  KO 
MEFs, followed by p53 KD MEFs and then by control in-
fected MEFs (Fig. S2 A).
As demonstrated by others and in our experiments, p53 
deficiency significantly increases the reprogramming rate of 
MEFs. However, it should be noted that loss of p53 function 
in human tumors is predominantly mediated by missense 
mutations, of which some were shown to possess novel 
properties. Therefore, it was of interest to examine whether 
Nanog was reported in various tumors (Clark, 2007; Gu et al., 
2007). Lin28, a factor required for reprogramming of human 
cells, also promotes transformation and plays a role in germ 
cell malignancies (Viswanathan et al., 2009; West et al., 2009). 
Furthermore, aggressive poorly differentiated human tumors 
were shown to express an ESC-like gene signature (Ben-Porath 
et al., 2008). These observations may derive from the role of 
stemness-inducing  factors  in  maintaining  high  self-renewal 
and proliferative capacities, the hallmark of cancer cells.
In attempts to improve reprogramming efficiency, Zhao   
et al. (2008) demonstrated that the combination of p53 knock-
down (KD) and Utf1 overexpression increases the efficiency of 
human iPSC generation (Zhao et al., 2008). The tumor sup-
pressor p53, known as the guardian of the genome, is pivotal 
for cell cycle control and apoptosis (Levine and Oren, 2009) 
and was shown to control various differentiation programs of 
stem and progenitor cells (Molchadsky et al., 2008). Recent 
data demonstrate that p53 counteracts reprogramming via the 
well characterized p53 downstream pathways, namely induc-
tion of cell cycle arrest and apoptosis in DNA-damaged cells, 
ensuring the genomic integrity of the generated iPSC (Hong 
et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marión   
et al., 2009; Utikal et al., 2009). In contrast, Hanna et al., (2009) 
claimed that p53 does not play a direct role in this process, and 
its effect is only a result of its function as a regulator of the pro-
liferation rate of the cells. In other words, in p53-deficient cells 
the enhanced efficiency of reprogramming is in direct propor-
tion to the increase in their proliferation rate.
p53 was also implicated in the core regulatory circuitry of 
ESCs. For example, p53 suppresses Nanog expression upon 
DNA damage in ESCs, resulting in their differentiation, 
thereby preventing them from proliferating in the presence of 
oncogenic stress (Lin et al., 2005). Moreover, activated p53 in-
duces differentiation of human ESCs (Maimets et al., 2008). 
These studies are in agreement with the general notion that 
p53 is a growth-suppressor gene, and as such exerts its sup-
pressing activity also in the reprogramming process. In that   
respect, p53 deficiency might exhibit a similar trait as overex-
pression of reprogramming factors, which may function both 
to promote reprogramming and, in the appropriate environ-
ment, exert an oncogenic activity. In other words, although in-
activating p53 facilitates reprogramming, its reduced activity 
may also promote tumor development.
Mutations in p53 constitute a cornerstone in tumorigenesis. 
In this context, several p53 mutants were demonstrated to not 
only lose their WT function but also to acquire new properties, 
including the ability to interfere with the function of WT p53 
and its family members, as well as additional p53-independent 
oncogenic functions. This notion is termed gain of function 
(GOF; Brosh and Rotter, 2009). Indeed, a long list of in vitro 
studies are now being confirmed by the conclusive data ob-
tained from animal models (Lang et al., 2004; Olive et al., 2004; 
Terzian et al., 2008), showing that mutant p53 (mut-p53) 
germline animals are highly permissive to the development of 
aggressive cancers. A clue linking mut-p53 and reprogramming 
may reside in the finding that mut-p53 can interfere with cell JEM VOL. 207, September 27, 2010 
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the R175H hotspot mutation in humans (p53R172H). These 
p53R172H MEFs, as well as p53 KO and WT p53 MEFs, were 
infected with retroviruses encoding Oct4, Sox2, Klf4, and 
GFP  (p53R172H+3F,  p53  KO+3F,  and  WT  p53+3F).   
As demonstrated in Fig. 1 A, the colony number displaying 
mut-p53 plays a role along this process. To that end, we com-
pared the reprogramming patterns of MEFs derived from   
p53 KO mice to those of MEFs derived from homozygous 
mut-p53 knockin mice, harboring an arginine-to-histidine 
substitution at aa 172 (Lang et al., 2004), corresponding to 
Figure 1.  The efficiency of reprogramming with three factors is enhanced by p53R172H. (A, Left) WT p53, p53 KO, and p53R172H MEFs were infected with 
retroviruses encoding Oct4, Sox2, and Klf4 (three factors) and assayed for AP activity. Numbers indicate the mean amount of AP-positive colonies ± SE, obtained 
from duplicate plates. (A, Right) Clones with ES-like morphology were analyzed for Nanog expression by quantitative real-time PCR (QRT-PCR) at the indicated time 
points. The chart shows the percentage of Nanog-positive clones. Upon appearance of Nanog-positive clones in a certain MEF type, we maintained only these 
clones. Hence, measurement of Nanog-positive percentage is not applicable (N/A) for later time points. (B) Nanog mRNA relative expression, measured by QRT-PCR, 
4 wk after infection in selected p53 KO and p53R172H iPS clones. ESCs served as a positive control. Results indicate the mean ± SD of two duplicate runs. A represen-
tative experiment out of three independent infections is shown for A and B. (C) In vitro differentiation of representative p53 KO+3F and p53R172H+3F clones (#107 
and #m-11, respectively) into the three germ layers: mesoderm (smooth muscle, stained with smooth muscle actin [SMA] antibody), ectoderm (neurons, stained 
with -III-tubulin antibody), and endoderm (hepatic cells, stained with -fetoprotein [AFP] antibody). Bars, 50 µm. A representative experiment out of two is shown.2130 Mutant p53 in reprogramming and malignancy | Sarig et al.
into iPSC. Surprisingly, p53 KO+3F or p53R172H+3F MEFs, 
which exhibited pluripotent capacity in vitro, formed malig-
nant tumors instead of teratomas. Specifically, injection of 
three representative p53 KO+3F clones (#w-103, 104, and 
106) resulted in rapid growth of aggressive sarcomas (n = 6) 
with no apparent differentiated regions, whereas injection of 
two other p53 KO+3F clones (#110 and 103) resulted in 
formation of aggressive sarcomas (n = 4) with very limited 
differentiation capacity, giving rise to rare keratin foci (Fig. 3 A). 
Furthermore, injection of five p53R172H+3F clones resulted 
in rapid development of sarcomas (n = 5; clones #w-212, 
213, and 204) or mixed tumors (n = 4; clones #m-7 and 11), 
consisting of malignant mesoderm with large regions of ecto-
dermal differentiation, mostly into keratin (Fig. 3 B). This is 
in contrast to the benign teratomas we obtained by the injec-
tion of reprogrammed clones derived from WT, short hair-
pin (sh) control, and sh-p53–infected MEFs (Fig. S1). The 
cells were injected subcutaneously and the malignant tumors 
that resulted from this injection grew very rapidly (4–6 wk), 
necessitating euthanasia for ethical reasons. This time span is 
probably too short of the development of metastasis. However, 
alkaline phosphatase (AP) activity was significantly higher 
in  p53R172H+3F  MEFs  compared  with  p53  KO+3F  and 
WT  p53+3F  MEFs.  Moreover,  although  80%  of  isolated 
p53R172H+3F clones expressed Nanog already 4 wk after in-
fection, none of the p53 KO+3F or WT p53+3F clones ex-
pressed Nanog at that time and started to accumulate it only   
6 wk after the infection (Fig.1, A and B). It should be noted 
that reprogramming is a stochastic process, and quantifying 
the efficiency and timescales of this process has been prob-
lematic because of the cellular and genetic heterogeneity of 
de novo–infected somatic cells (Hanna et al., 2009; Yamanaka, 
2009). Additionally, reprogrammed cells accumulate Nanog ex-
pression throughout the process. The kinetics of this accumula-
tion is dependent upon the combined conditions of the specific 
reprogramming experiment (Jaenisch and Young, 2008). There-
fore, it was important to use the same infection mixture for the 
compared cell types at the same time. The kinetic of reprogram-
ming in our hands ranged between 4 and 6 wk. It is of note that 
because of the heterogeneity of each reprogramming process, 
and to validate our experiments, we conducted several experi-
ments for each cell type with the different combinations of fac-
tors. These experiments were repeated under the same conditions 
using various batches of MEFs isolated from different mice. The 
pluripotency of both p53 KO+3F and p53R172H+3F clones was 
exhibited by their ability to undergo differentiation into cells of 
the three germ layers in vitro (Fig. 1 C). Overall, as summarized 
in Fig. 1, p53R172H MEFs were reprogrammed more efficiently 
than the other groups.
To exclude the possibility that the enhanced reprogram-
ming of p53 KO or mutant MEF stems from increased infec-
tion yield, we measured GFP expression immediately after 
the infection. As shown in Fig. 2 A, the infection yield was 
similar in all three cell types (WT, KO, and mutant MEFs).   
It was recently suggested that the number of cell divisions   
is a key parameter controlling somatic cell reprogramming 
(Hanna et al., 2009). To determine whether p53 influences 
reprogramming via its affect on proliferation, we measured 
the proliferation rate of WT p53 MEFs compared with p53 
KO MEFs. This revealed that despite the significantly higher re-
programming efficiency, the proliferation rate of p53-deficient 
MEFs was only three times higher than those of WT MEFs. 
Importantly, there was no growth advantage to mut-p53 
MEFs over p53 KO MEFs (Fig. 2 B), although the former 
exhibit a dramatic increase in reprogramming efficiency. This 
clearly indicates that the reprogramming-promoting function 
of mut-p53 is not mediated via enhancement of proliferation, 
and it suggests that mut-p53 has a direct role in the reprogram-
ming process.
In vivo growth of p53 KO and p53R172H clones 
reprogrammed by Oct4, Sox2, and Klf4
One of the hallmarks of iPSCs is their ability to form benign 
teratomas in Nude mice. A major concern using p53-deficient 
cells for reprogramming is their potential to undergo onco-
genic transformation. Therefore, we focused on the in vivo 
fate of p53-deficient somatic cells that were reprogrammed 
Figure 2.  Mut-p53 does not enhance MEF infection efficiency or   
possess a GOF activity in promoting MEF proliferation. (A) p53 KO, 
p53R172H, and WT MEFs were infected with three factors and GFP.  
The percentage of cells expressing GFP was measured 5 d after infec-
tion by flow cytometry. Noninfected MEFs were used as a negative 
control. A representative experiment out of two independent infec-
tions is shown. (B) Cumulative population doubling of uninfected  
WT p53, p53 KO, and p53R172H MEFs. A representative experiment  
out of two is shown.JEM VOL. 207, September 27, 2010 
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late-passaged  clones  and  showed  similar 
histological  properties.  However,  tumor 
development  was  faster  using  late-passage 
clones (unpublished data).
The observation that p53 deficiency in 
MEFs diverts the reprogramming process 
toward malignant transformation led us to 
search for the underlying oncogenic driv-
ing force during the process of aberrant   
reprogramming. It was previously demon-
strated that Klf4 could function as a tumor 
suppressor or an oncogene, depending on 
the cellular context (Evans and Liu, 2008). 
Therefore, we examined whether Klf4 ex-
presses  its  oncogenic  activity  when  introduced  into  p53- 
deficient MEFs. We infected either p53 KO or p53R172H MEFs 
with retroviruses encoding Klf4 and injected a pool of in-
fected cells into Nude mice. This resulted in rapid formation 
of aggressive sarcomas (Fig. 3 C), whereas injection of non-
infected p53 KO or p53R172H MEFs into Nude mice did not 
give rise to any tumors. These data indicate that Klf4 is capa-
ble of transforming p53 KO and p53R172H MEFs. Notably, 
WT p53 MEFs senesced either in the absence or presence 
of Klf4 overexpression and, thereby, could not have formed 
tumors in mice. In addition, overexpression of Klf4 in sh-p53 
MEFs did not give rise to tumors up to 5 mo after infection. 
It should be noted that injection of only 100 cells from se-
lected reprogrammed clones, or from p53 KO/p53R172H MEFs 
overexpressing Klf4, resulted in tumor formation as well 
(Table I). Furthermore, we have generated several cell lines 
derived from selected tumors and injected these cells into 
Nude mice to determine the potential of these tumor-derived 
cell lines to give rise to secondary tumors. As shown in Table I, 
we  obtained  secondary  tumors  from  p53R172H+3F  clones. 
we have thoroughly analyzed the invasive front of the various 
tumors summarized in Table S1. While all benign tumors did 
not show invasiveness, most of the malignant tumors grew in 
an infiltrative manner (Fig. S3). A full description of the tu-
mors is summarized in Table S1. Combined, these in vitro 
and in vivo experiments suggest that complete p53 elimina-
tion or mutation not only enhances reprogramming induced 
by the three factors but also alters the nature of the repro-
grammed cells, granting them cancer-forming potential.
All reprogrammed clones were selected for isolation and 
further characterization according to their morphology. In-
terestingly, although the selected clones of both p53 KO and 
p53R172H showed typical iPSC morphology at lower passages, 
at  later  passages  several  clones  changed  their  morphology 
and, instead of forming colonies with clear-cut round edges, 
spread and gave rise to amorphous-shaped colonies, which 
kept proliferating and took over the culture. Despite this dra-
matic change in morphology and growth control, the exoge-
nous GFP was properly silenced in these clones. (Fig. S4). 
Importantly, malignant tumors developed from both early- and 
Figure 3.  In vivo tumor formation by p53 
KO+3F and p53R172H+3F clones and by Klf4-
overexpressing p53 KO and p53R172H MEFs.  
(A, Left) A representative hematoxylin and eosin 
(H&E) section obtained from a typical sarcoma 
generated by a p53 KO+3F clone (#w-106). Arrows 
point at cells undergoing mitosis. (A, Right) A rep-
resentative section of clone #110 that formed  
a sarcoma, within which were rare foci of keratin 
(arrowhead). Shown are representative sections  
out of 10 tumors that were analyzed. (B) Sarcoma 
(left) and a tumor containing large differentiated 
regions of keratin (right) generated by p53R172H+3F-
reprogrammed clones (#w-212 and #m-7,  
respectively). Shown are representative sections  
out of nine tumors that were analyzed. (C) Typical 
sarcomas generated by Klf4-overexpressing p53  
KO MEFs (left) and p53R172H MEFs (right). Arrows 
point at mitotic figures. Shown are representative 
sections out of two tumors analyzed for each  
cell type. The exact numbers of total tumors  
analyzed out of each representative clone are  
summarized in Table S1. Bars, 50 µm.2132 Mutant p53 in reprogramming and malignancy | Sarig et al.
with some minor insertions (Table S2), suggesting that the pres-
ence of p53 is essential for maintaining the genomic integrity 
of reprogrammed cells.
A novel GOF of mut-p53 in reprogramming cells using only 
Oct4 and Sox2
As p53 was shown to be a negative regulator of Nanog (Lin   
et al., 2005; Rowland et al., 2005) and Klf4 was shown to 
suppress p53 expression, it was previously hypothesized that 
Klf4 may contribute to reprogramming by its p53-suppressive 
activity. Providing that this assumption is correct, Klf4 should 
be dispensable for reprogramming of p53 KO MEFs. Although 
p53-deficient fibroblasts were reprogrammed with only Oct4 
and Sox2, albeit with lower efficiency (Kawamura et al., 
2009), another group reported that Klf4 is essential for repro-
gramming p53-deficient fibroblasts (Zhao et al., 2008). Be-
cause of the oncogenic activity of Klf4, which was manifested 
in p53-deficient cells, we examined whether reprogramming 
of p53-deficient MEFs with only Oct4 and Sox2 will result in 
the formation of normal iPSC. In agreement with Zhao et al. 
(2008), we found that Klf4 is essential for reprogramming of 
p53 KO MEFs because 2 mo after infection there was only a 
slight increase in expression of stemness markers in isolated 
clones (unpublished data). However, prolonged culturing of 
these clones (for 5 mo) resulted in the establishment of four 
clones that exhibited iPSC characteristics, including expres-
sion of stemness markers (Fig. 4 A). The pluripotency of 
these clones was evident by their ability to differentiate 
into cells of the three germ layers in vitro and to form terato-
mas in vivo (Fig. 4, B and C, respectively). Surprisingly, a 
careful examination of the histopathology of the teratomas 
revealed that five out of seven tumors derived from these 
clones (#202–6, 202, 203, and 226) contained various levels 
of malignant mesenchyme characteristic of teratocarcinoma 
instead of benign teratoma (Fig. 4 D). Moreover, one of the 
injected clones (#226) that gave rise to a teratocarcinoma also 
gave rise to a tumor comprising both sarcoma and carcinoma 
These tumors maintained the characteristics of their paren-
tal tumors, i.e., either a sarcoma (#w-212) or a tumor with 
regions of ectodermal differentiation, mostly into keratin, 
and malignant mesoderm (#m-11; unpublished data). It is 
of note that the injection of only 10 cells of p53 KO+Klf4 
tumor–derived cells was sufficient to induce tumor forma-
tion, indicating the high tumorigenic potential of these 
cells. Combined, these results clearly show that in p53- 
deficient primary MEFs, Klf4 can exert its oncogenic po-
tential and that the malignant phenotype of reprogrammed 
cells generated by the three factors in a p53-deficient envi-
ronment may be attributed to the oncogenic activity mediated 
by Klf4.
One of the hallmarks of p53 is to maintain chromosomal 
integrity and stability. To further characterize the effect of 
p53 deficiency on the genomic stability of reprogrammed 
cells, we used spectral karyotyping analysis of representative 
clones used throughout our studies. As expected, the karyo-
type of WT MEFs, even at low passages, is very unstable, 
comprising several chromosomal duplicates in most of the 
cells (Table S2). This chromosomal instability of normal 
primary cultures of mesenchymal stem/progenitor cells is 
well known and does indicate the cells’ tumorigenic poten-
tial (Tolar et al., 2007; Foudah et al., 2009; Holland and 
Cleveland, 2009; Josse et al., 2010). To gain tumorigenic 
potential, the cells must acquire additional mutations in spe-
cific oncogenes/tumor suppressors. Indeed, as mentioned 
before, injection of p53 KO and mutant MEFs, which dis-
play similar levels of chromosomal instability, did not result 
in tumor formation.
The karyotype picture was identical in p53 KO and   
mutant MEFs, yielding the same abnormal chromosomal num-
ber as WT-MEFs. Interestingly, however, although repro-
grammed cells originating from p53 KO and mutant MEFs 
retained this chromosomal abnormality, reprogrammed cells 
originating from either WT MEFs, or even from p53 KD 
MEFs, exhibited a rather normal chromosomal picture, albeit 
Table I.  Tumor forming potency of the divergent cell types
Cell type 100 cells 1,000 cells 10,000 cells
p53R172H+3F (#m-11) 1/4 1/4 4/4
p53R172H+3F (#w-212) 3/4 4/4 N/A
p53R172H+2F (#T-15) 1/2 2/2 1/2
p53 KO+2F (#226) 0/4 2/2 1/2
p53 KO+3F (# 103) 3/4 3/4 2/4
sh-con+3F (#I) 1/2 0/2 0/2
p53 KO Klf4 4/4 4/4 N/A
p53R172H Klf4 1/2 1/2 N/A
sh-p53+ Klf4 0/4 0/2 0/2
Tumor-derived #m-11 1/2 N/A N/A
Tumor-derived #w-212 1/2 N/A N/A
Tumor-derived p53 KO Klf4 1/2 (also 1/2 after injection of only 10 cells) N/A N/A
The potency of the designated cell types to form tumors was analyzed by subcutaneous injection of various amounts of the designated cells (100, 1,000, or 10,000 cells)  
into Nude mice. Indicated are the numbers of animals out of total animals analyzed in which a tumor developed within 4 mo. For some cell types, only low numbers of cells 
were injected; therefore, estimation of tumor formation following injection of high numbers of cells was not applicable (N/A).JEM VOL. 207, September 27, 2010 
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capacity of reprogramming by three factors. Indeed, the total   
number of clones with typical iPSC characteristics was signifi-
cantly enhanced in p53R172H MEFs compared with p53 KO and 
WT p53 MEFs reprogrammed with Oct4 and Sox2 (p53R172+2F, 
p53 KO+2F, and WT p53+2F; Fig. 5 A). Moreover, 16 of the 
19 (84%) isolated p53R172H+2F clones expressed high levels of 
Nanog already 50 d after the infection, whereas none of the 12 
selected p53 KO+2F clones expressed Nanog at the same time 
point (Fig. 5 B). In addition to Nanog, all selected p53R172H+2F 
clones expressed high levels of endogenous Oct4 and Sox2, 
whereas only some of the selected p53 KO+2F clones expressed 
cells, with no detectable differentiated regions (Fig. 4 D). 
These data suggest that the p53 KO clones that were repro-
grammed with only Oct4 and Sox2 (excluding Klf4) repre-
sent a population of pluripotent cells with the capacity to 
initiate the formation of both benign and malignant tumors. 
It should be noted that no clones were formed when WT-
p53 or sh-p53 MEFs were used under the same experimental 
conditions (unpublished data).
Because reprogramming of p53 KO cells with only two 
factors is an extremely inefficient process, we wondered whether 
mut-p53 will enhance its efficiency, similar to its enhancing the 
Figure 4.  Reprogramming of p53 KO MEFs with Oct4 and Sox2. (A) Relative expression of mRNA encoding endogenous stemness markers Fbxo15, Sox2, 
and Oct4 was measured by QRT-PCR 5 mo after infection of MEFs with retroviruses encoding Sox2 and Oct4. iPS clones that appeared 5 mo after infection are indi-
cated. Uninfected MEFs are used as negative controls and ESCs as a positive control. The results are represented by the mean ± SD of two duplicate runs from a 
representative experiment out of two individual infections. (B) In vitro differentiation into cells of the three germ layers of a representative p53 KO+2F clone (#202-3). 
Markers used are described in Fig. 1 C. Bars, 100 µm. Shown is a representative experiment out of two. (C) Representative H&E sections of a teratoma formed from a 
p53 KO+2F clone (#202-3) with representation of the three germ layers. (D, Left) irregular islands of epithelial differentiation showing marked dysplasia and high 
mitotic rate (arrowheads) in a tumor generated by the p53 KO+2F clone #226. In the center of the field there is a band of plump spindle cells (mesoderm), including 
one mitotic figure (arrow). Shown is a representative of five tumors showing various levels of malignancy. (D, Right) The inset magnification depicts a group of  
malignant epithelial cells (carcinoma). To their left are malignant spindle cells of mesodermal origin (sarcoma). Arrows indicate mitotic figures. Bars, 50 µm.2134 Mutant p53 in reprogramming and malignancy | Sarig et al.
MEFs reprogrammed by three factors. 
Thus, p53R172H exhibits an additional 
GOF activity by compensating for the 
lack  of  Klf4  in  efficient  reprogram-
ming and may be considered as a re-
programming factor.
In an attempt to unveil the mecha-
nism underlying the newly dependent 
unidentified activity of p53R172H in re-
programming, we measured the basal 
levels of stemness factors in p53R172H 
MEFs. Interestingly, these MEFs ex-
pressed  higher  basal  levels  of  Nanog, 
Sox2, and Oct4 than p53 KO and WT 
p53 MEFs (Fig. 5 C). Immunostainings 
of WT p53, p53 KO, p53R172H MEFs, 
and  ESC,  using  antibodies  against 
Oct4, Sox2, and Nanog, detected the 
expression of endogenous Oct4, Sox2, 
and Nanog in ESCs but failed to detect any endogenous ex-
pression by p53R172H MEFs (unpublished data). This suggests 
that the higher basal levels observed by RT-PCR may reflect 
a moderate increase in the expression of these genes in the 
entire population rather than pronounced increase in few cells. 
Because the expression of these genes by p53R172H MEFs is 
much lower than the levels expressed by ESCs (1/10), their 
encoded proteins probably cannot be detected by the com-
mercial antibodies used. As demonstrated for adult neural stem 
cells (Kim et al., 2009), the increased basal expression levels of 
these stemness factors in p53R172H MEFs might render them 
more prone to reprogramming.
Finally, selected p53R172H+2F clones were further charac-
terized for their pluripotent capacity. As demonstrated in   
Fig. 6 A, they were able to differentiate into cells of the three 
germ layers in vitro. However, injection of these clones into 
Nude mice resulted in the development of tumors similar to 
these genes at the same time and to a lower extent (Fig. 5 B). 
The morphology of p53R172H+2F clones and p53 KO+2F 
clones was typical to that of normal iPSC. However, although in 
most of the p53R172H+2F clones the exogenous GFP was si-
lenced 24 d after the infection, p53 KO+2F clones still expressed 
GFP at that stage (Fig. S5), and silencing occurred only at a later 
culturing period (not depicted). These results suggest a novel 
GOF property for mut-p53 in the process of reprogramming.
As described, Klf4 was suggested to contribute to repro-
gramming by the suppression of p53. However, the repro-
gramming efficiency of p53-deficient fibroblasts with only 
two factors was much lower compared with WT-p53 fibro-
blasts reprogrammed with three factors. As p53 KO did not 
substitute for Klf4, it is clear that, besides p53 suppression, Klf4 
promotes reprogramming by additional mechanisms. In con-
trast, in the presence of p53R172H, the efficiency of reprogram-
ming with only two factors was even higher than WT-p53 
Figure 5.  GOF of mut-p53 in enhancing 
the reprogramming efficiency of MEFs 
using only Oct4 and Sox2. (A) Comparison 
of reprogramming efficiency of WT p53 (WT), 
p53 KO, and p53R172H MEFs by retroviruses 
encoding Oct4 and Sox2. After infection, 
clones with typical iPSC characteristics in vitro 
were counted at the indicated time points.  
(B) Comparison of Nanog (top) and endog-
enous Sox2 and Oct4 mRNA (bottom) ex-
pression between selected p53 KO+2F and 
p53R172H+2F clones, measured by QRT-PCR 50 d 
after infection. A representative experiment 
out of three individual infections is shown for 
A and B. (C) Basal expression levels of mRNA 
encoding stemness markers Nanog, Sox2, and 
Oct4 in WT p53, p53 KO, and p53R172H MEFs.  
A representative experiment out of at least five 
independent analyses of MEFs derived from 
various preparations is shown. Results indicate 
the mean ± SD of two duplicate runs.JEM VOL. 207, September 27, 2010 
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This  may  explain  the  discrepancy   
between in vitro and in vivo results. 
Although  in  vitro  mut-p53  is  not 
accumulated and, thereby, does not   
abrogate proper differentiation of the 
reprogrammed cells, its accumulation 
in vivo probably results in its enhanced activation, which may 
lead to perturbation of differentiation, eventually resulting in 
formation of malignant tumors. Analyses of the pattern of mut-
p53 expression in the tumors revealed that it is expressed only by 
part of the tumor cells (Fig. 7 C), suggesting that its expression/
activation is regulated within the tumor and associated with 
selected tumor cell populations. It is of note that in some tu-
mors its expression was excluded from differentiated regions 
(Fig. 7 C, top).
DISCUSSION
In this study, we reprogrammed a series of MEFs differing in 
their p53 status, which greatly influenced both the efficiency 
of reprogramming and the nature of the reprogrammed cells 
(Fig. S6 and Table S1). The tumor suppressor p53, which 
plays a pivotal role in maintaining genome fidelity (Levine 
and Oren, 2009), was recently demonstrated to counteract 
somatic cell reprogramming (Zhao et al., 2008; Hong et al., 
2009; Kawamura et al., 2009; Li et al., 2009; Marión et al., 
2009; Utikal et al., 2009). Specifically, inhibiting p53 activity, 
using strategies such as KD, KO, or overexpression of dominant- 
negative forms, increased reprogramming efficiency of a vari-
ety of mouse and human somatic cells. However, considering 
the role of p53 as a genome caretaker, its deficiency may lead 
not only to the acceleration of reprogramming but also to on-
cogenic transformation of the iPSCs generated, diminishing 
their therapeutic potential. Because p53 is mostly mutated in 
tumors and mut-p53 was shown to possess novel activities, 
our major goal was to study the role of mut-p53 in this 
process and to follow the in vivo fate of reprogrammed p53-
deficient somatic cells. In agreement with the aforementioned 
studies, we found that reduction in p53 levels accelerated typ-
ical reprogramming of MEFs. In our initial experiments we 
those  obtained  from  p53R172H  clones  reprogrammed  with 
three factors, i.e., tumors with limited differentiation capacity, 
mainly to keratin and epithelial tissues, surrounded by highly 
malignant mesenchyme and invasive front (n = 6; clones   
#t-15, t-20, and t-4; Fig. 6 B and Fig. S3). In addition, one 
clone (#t-8) gave rise to sarcomic tumors (n = 2) with no differ-
entiation (Fig. 6 B). Thus, in addition to the GOF activity of 
p53R172H in enhancing the efficiency of the process, p53R172H+2F 
clones differ from p53 KO+2F in their characteristics. Although 
p53 KO+2F clones still maintain their pluripotential capacity 
in vivo, p53R172H+2F clones exhibit very limited differentia-
tion capacity.
Activation of mut-p53 in tumors formed by reprogrammed 
p53R172H MEFs
Accumulation of the p53 protein in mut-p53 knockin mice 
was demonstrated to occur only in tumors and transformed 
cells and not in normal tissues (Lang et al., 2004; Terzian   
et al., 2008; Wang et al., 2009). Moreover, ample data indicate 
that stabilization and accumulation of mut-p53 enhances its 
dominant-negative and GOF abilities (Brosh and Rotter, 2009). 
Therefore, we wondered whether mut-p53 protein level is al-
tered during the processes of in vitro reprogramming and in vivo 
tumor formation. We found that p53R172H-reprogrammed 
clones exhibited similar mut-p53 protein levels to their paren-
tal p53R172H MEFs (Fig. 7 A). However, comparison of three 
pairs of p53R172H-reprogrammed clones to the tumors derived 
from these clones revealed that mut-p53 is stabilized in those 
tumors (Fig. 7 B). Specifically, although the clones growing in 
vitro express a single form of p53 of comparable size and level 
to that found in their parental p53R172H MEFs, their cor-
responding tumors accumulate several p53 forms, which 
may represent activated mut-p53 (Brosh and Rotter, 2009). 
Figure 6.  p53R172H cells reprogrammed 
with Oct4 and Sox2 lose their differentia-
tion capacity in vivo. (A) In vitro differentia-
tion into cells of the three germ layers of a 
representative p53R172H+2F clone (#t-15). 
Markers used are described in Fig.1 C. Bars,  
25 µm. A representative experiment out of 
two is shown. (B) Representative sections  
obtained from tumors formed by p53R172H+2F 
clones. Left, a sarcoma containing large  
regions of ectodermal differentiation (#t-15). 
Right, a sarcoma without any differentiation 
(#t-8). Bars, 100 µm. Shown are representa-
tive sections out of eight tumors that were 
analyzed. The exact numbers of total tumors 
analyzed out of each representative clone are 
summarized in Table S1.2136 Mutant p53 in reprogramming and malignancy | Sarig et al.
p53R172H+2F clones lost their differentiation capacity in vivo, 
giving rise mainly to sarcomas.
As for the reported duality of Klf4, which, depending   
on the cellular circumstances, may function either as a tumor 
suppressor or an oncogene (Evans and Liu, 2008), in our study 
Klf4 functions as an oncogene, as its overexpression alone in 
either p53 KO or p53R172H MEFs induced aggressive tumors. 
Moreover, even in the presence of its reprogramming partners 
(Oct4 and Sox2), Klf4 seems to possess oncogenic potential, as 
p53 KO+2F clones could form well differentiated tumors, 
whereas p53 KO+3F clones formed only poorly differentiated 
sarcomas. It should be noted that although the exogenous 
genes are silenced during the process, the silencing takes place 
only after cells are already reprogrammed and start to express 
DNA methyltransferases (Takahashi and Yamanaka, 2006). 
Thereby, expression of oncogenes in this process, even at 
early stages, may contribute to the formation of malignant 
cells. Additionally, this is in accordance with previous data 
demonstrating the high oncogenic activity of c-Myc, which 
was shown to accelerate reprogramming, yielding iPSC, 
which gave rise to mice with high incidence of cancer caused 
by reactivation of the c-Myc transgene (Okita et al., 2007). 
Thus, reactivation of the Klf4 transgene may contribute to   
tumor formation in vivo. Accordingly, we analyzed whether 
Oct4 and Sox2 possess oncogenic activity as well. For that, p53 
KO and mut-p53 cells were infected with either Oct4 or Sox2, 
and the pool of infected cells was injected to Nude mice.   
Although injections with Sox2-infected cells did not give rise 
reprogrammed MEFs using the three factors: Oct4, Sox2, and 
Klf4. This resulted in a gradual p53-dependent increase in the 
reprogramming efficiency of MEFs as follows: WT-p53 <   
sh-p53 < p53 KO < p53R172H. This pattern was even more pro-
nounced when only two factors, Oct4 and Sox2, were used. 
Although under in vitro conditions no major differences in 
the general characteristics of these clones were noticed, their 
injection into mice revealed differences in the nature of these 
cells. In contrast to WT-p53 and sh-p53 cells, the complete 
p53 elimination or the expression of its mutated form resulted 
in reprogrammed cells that, along with their pluripotential ca-
pacity, embodied tumorigenic potential. These typical repro-
grammed single-cell clones, when injected into mice formed 
tumors that exhibited a mixed phenotype, comprising both 
differentiated regions and highly malignant cells. Overall, the 
increase in reprogramming efficiency correlates with the ca-
pacity of these clones to form aggressive tumors.
Mut-p53 exhibits a novel GOF by enhancing the effi-
ciency of reprogramming with three factors, and a more 
prominent GOF emerges by using only 2Fs. Although the 
generation of p53 KO+2F clones is a very inefficient process, 
the presence of mut-p53 compensated for the lack of Klf4, 
yielding high numbers of reprogrammed clones in a relatively 
short period. This novel activity of mut-p53 was accompanied 
not only by affecting the process quantitatively but also by 
changing the qualitative features of the reprogrammed cells. 
Although p53 KO+2F clones maintained their pluripotential 
capacity in vivo, and gave rise to teratomas and teratocarcinomas, 
Figure 7.  p53R172H-reprogrammed cells form tumors that accumulate mut-p53 in restricted regions. (A) A Western blot depicting the level of 
mut-p53 in p53R172H MEFs and selected p53R172H-reprogrammed clones (reprogrammed by two or three factors, as indicated). (B) A Western blot depicting 
mut-p53 accumulation in tumors derived from p53R172H clones (reprogrammed by two or three factors, as indicated). (C) Representative tumor sections 
derived from p53R172H-reprogrammed clones were stained with anti-p53 (brown). The stained sections were counterstained with hematoxylin (blue). Top, 
the most well differentiated cells, arranged as a band (asterisks), possibly tumor stroma, do not express p53. Bar, 200 µm. Bottom, intensive positive stain-
ing for mut-p53 is present in some but not all neoplastic cells. Arrows indicate differentiated regions of keratin foci. Bar, 400 µm. Stainings were per-
formed using five different tumors.JEM VOL. 207, September 27, 2010 
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and cancer-forming cells at different ratios. It is therefore im-
portant to note that as long as there are no reliable markers to 
distinguish between normal stem cells and cancer-forming 
cells, it is difficult to asses the actual balance between stem-
ness and cancer that will be expressed in vivo. Indeed, there 
is an increasing body of evidence supporting the notion that 
tumors are populated by fractions of cells with stem cell–like 
properties (Reya et al., 2001; Kim and Dirks, 2008). This has 
been shown for certain leukemias (Lapidot et al., 1994) and 
breast (Al-Hajj et al., 2003) and brain (Amariglio et al., 2009) 
tumors. Furthermore, it was also shown that leukemic stem 
cells express antigens similar to those expressed by hemato-
poietic stem cells (Taussig et al., 2005). It was also suggested 
that most tumors arise from the maturational arrest of a cellu-
lar lineage derived from a tissue stem cell (Sell, 2004), provid-
ing links between stem cells, tumor-initiating cells, and cancer 
formation. Accordingly, we observed that reprogramming of 
MEFs may give rise to cells which display characteristics of 
either stem cells or cancer cells at various ratios, depending 
on p53 status. As somatic cells are continuously exposed to 
external and internal genotoxic stress, the relatively low inci-
dence of tumor development is puzzling unless we assume 
that there is another significant barrier on the path to cancer. 
Based on our findings, we speculate that a productive malig-
nant transformation is also dependent on the genomic elastic-
ity of cells. Stem cells, having unstable genomes, provide such a 
suitable cellular environment for a productive transformation. 
In fact, to permit the pluripotency of stem cells, genomic elastic-
ity is required (Hochedlinger and Plath, 2009). It is therefore 
possible that under such flexible genomic conditions, loss of 
genomic stability, such as that mediated by p53 loss or muta-
tion, may be abused by oncogenes to override normal cellular 
fate and, instead, embark on the chaotic road toward malig-
nant transformation. This may underlie the high incidence of 
cancer development in Li-Fraumeni syndrome patients, who 
usually bear germline mutations in p53 (Malkin et al., 1990; 
Srivastava et al., 1990).
Recently, the six essential features characteristic of can-
cer cells, suggested by Hanahan and Weinberg (2000), were 
revisited (Lazebnik, 2010). The major difference between cancer-
ous and benign tumors is the tissue invasion and metastatic 
features of the former. ESCs and iPSCs can form benign   
tumors. However, the presence of mut-p53 tips the scale   
toward the formation of malignant tumors, or, in other words, 
toward  cancer  formation.  Establishing  these  divergent 
clones, with the capacity to induce either benign or malig-
nant tumors with various differentiation capacities, may 
serve as a platform to answer the challenging question of the 
mechanism underlying the key emergent property of cancers: 
their malignancy.
In sum, our present study shows that p53 plays both a 
quantitative  role,  determining  the  efficiency  of  reprogram-
ming, and a qualitative regulatory role, determining the fidelity 
of the reprogrammed cells. Accelerating the process, without 
proper checkpoints enabling DNA damage repair or cell death 
of impaired cells, leads to the formation of reprogrammed cells 
to tumors, a small part of mice injected with Oct4-infected 
cells developed tumors (unpublished data). This may explain 
the tumorigenic potential of p53 KO+2F. However, although 
most p53 KO+2F clones gave rise to teratomas or teratocarci-
nomas, p53R172H+2F clones gave rise mostly to sarcomas, sug-
gesting that mut-p53 gains a novel activity and functions as an 
oncogene in this process. Mut-p53 was previously shown to 
hold a differentiation-blocking activity and to affect proper 
cellular maturation as well (Shaulsky et al., 1991; Matas et al., 
2004; Wang et al., 2009). Our results demonstrate the expres-
sion of mut-p53 in undifferentiated regions of the tumors 
(Fig. 7 C). Given that maturational arrest is suggested as a pos-
sible mechanism of cancer formation (Sell, 2004), the onco-
genic activity of mut-p53 in reprogramming may be attributed 
to its abrogation of differentiation function.
Our results are in agreement with the notion that differen-
tiation and malignant transformation may represent reciprocal 
situations. Reprogramming of somatic cells into ES-like cells 
requires precise orchestration between dedifferentiation, im-
mortalization, and the acquisition of pluripotency and self- 
renewal properties. Perturbation in the balance between these 
processes could lead to the acquisition of aberrant properties. 
The low efficiency of reprogramming may stem from the fact 
that during this multistep process, analogous to tumorigenesis 
(Hanahan and Weinberg, 2000), a cell lineage should stochas-
tically accumulate several genetic and epigenetic alterations. 
Indeed, there is a tight link between pluripotency and tumori-
genesis (Knoepfler, 2009). Reprogramming of cells malfunc-
tioned in their tumor-suppressing machinery may raise the 
probability of oncogenic transformation. One of the main func-
tions of p53 is to maintain chromosomal integrity and stability, 
which was previously shown to also occur in ESCs (Lin et al., 
2005). In addition, Marión et al. (2009) demonstrated the   
requirement of p53 to ensure the genomic integrity of iPSC. 
p53-null iPSC showed chromosomal instability and persistent 
damaged DNA, which was also demonstrated in teratomas 
derived from these cells. This suggests the possible malignancy 
of these tumors, although it was not further characterized. 
The  karyotype  analysis  of  the  various  reprogrammed  cells 
generated in our study revealed that although reprogrammed 
cells originating from p53 KO and mutant MEFs retained the 
chromosomal abnormality of the parental MEFs, repro-
grammed cells originating from WT MEFs, or even from p53 
KD MEFs, exhibited a rather normal chromosomal picture 
(Table S2). This suggests that, indeed, the presence of p53 is 
essential  for  reprogramming  of  selected  cells  with  normal 
chromosomal numbers (or harboring minor changes). Alter-
natively, it may also suggest that in the presence of WT p53, 
reprogrammed cells carrying gross chromosomal aberrations 
are eliminated from the population by either programmed cell 
death or growth arrest.
Our data show that a pluripotential capacity in vivo does 
not guarantee the fidelity of iPSC because reprogrammed 
clones that gave rise to teratomas held a potential to also 
form malignant tumors. These data suggest that the vari-
ous clones generated actually represent mixtures of stem cells 2138 Mutant p53 in reprogramming and malignancy | Sarig et al.
were removed 2–16 wk after injection, fixed in 4% paraformaldehyde, decalci-
fied, and embedded in paraffin blocks. Sections, taken from three levels, were 
stained with H&E. The designation of a tumor as benign or malignant was 
based on histological criteria. It took into account the cytological features of 
nondifferentiated stromal tissue composed of spindle-shaped cells. Tumors 
considered malignant were typically densely cellular, composed of pleomor-
phic cells with a high nuclear/cytoplasmic ratio, showed anisocytosis and an-
isokaryosis, and had a high mitotic rate. Many, but not all, showed an infiltrative 
growth pattern. In contrast, the stroma in benign tumors was typically well dif-
ferentiated and of low to intermediate cellularity. Its growth pattern was ex-
pansile, pushing rather than infiltrating surrounding tissues. Slightly malignant 
is admittedly an imprecise designation, indicating that the tumor showed fea-
tures intermediate between these two extremes.
Where indicated, cells collected from selected reprogrammed clones 
were diluted before injections (104/103/102/101 cells/50 µl, with Matrigel 
matrix at a ratio of 1:1). The tumors were removed 6–16 wk after injection 
and subjected to histology analyses as in the previous paragraph. Tumor- 
derived cell lines were generated out of part of the tumors by dissociating   
the tumor cells using a grid. The mashed tissue was grown on gelatin-coated 
plates, in ES medium. Animal protocols were approved by the Institutional 
Animal Care and Use Committee of the Weizmann Institute of Science.
Immunohistochemistry of tumor sections. Paraffin sections were de-
paraffinized using xylene and were rehydrated with alcohol series. The tissue 
was permeabilized using 0.5% Triton for 5 min. After three consecutive 
washes with PBS, the tissue was blocked using 3% BSA and 0.1% Triton   
X-100 in PBS for 60 min. The sections were stained with a polyclonal anti-
p53 antibody (prepared in our laboratory), overnight at room temperature. 
After three consecutive washes with PBS, the secondary antibody was added 
for 60 min at room temperature, washed with PBS, and the signal was de-
tected using DAB (Sigma-Aldrich) for 10 s. For counterstaining, sections 
were stained with hematoxylin. The sections were then dehydrated and 
mounted using xylene-based mounting medium.
Chimeric mice formation. Chimeric mice were formed as described in 
Sarig et al. (1999).
Online supplemental material. Figs. S1 and S2 describe the enhancement 
in the reprogramming process by either p53 KD or KO, respectively. Fig. S3 
depicts the malignant feature of selected clones by showing their invasive growth 
patterns compared with the noninvasive growth of benign tumors. Fig. S4 de-
scribes the change in morphology of late-passage p53 KO and mut-p53 clones. 
Fig. S5 further shows the GOF of mut-p53 in reprogramming of MEFs using 
only Oct4 and Sox2. Fig. S6 is a graphical summary of the results. Table S1 sum-
marizes the various cell types used in this study and their tumorigenic potential. 
Table S2 summarizes the karyotype analysis of selected clones. Table S3 is a list 
of primers used in this study. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20100797/DC1.
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